PMID- 33477482
OWN - NLM
STAT- MEDLINE
DCOM- 20210903
LR  - 20221207
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 26
IP  - 2
DP  - 2021 Jan 18
TI  - Lipolytic Postbiotic from Lactobacillus paracasei Manages Metabolic Syndrome in 
      Albino Wistar Rats.
LID - 10.3390/molecules26020472 [doi]
LID - 472
AB  - The current study investigates the capacity of a lipolytic Lactobacillus 
      paracasei postbiotic as a possible regulator for lipid metabolism by targeting 
      metabolic syndrome as a possibly safer anti-obesity and Anti-dyslipidemia agent 
      replacing atorvastatin (ATOR) and other drugs with proven or suspected health 
      hazards. The high DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS [2,2'-azino-bis 
      (3-ethyl benzothiazoline-6-sulphonic acid)] scavenging activity and high 
      activities of antioxidant enzyme such as superoxide dismutase (SOD), catalase 
      (CAT), and glutathione peroxidase (GSH-px) of the Lactobacillus paracasei 
      postbiotic (cell-free extract), coupled with considerable lipolytic activity, may 
      support its action against metabolic syndrome. Lactobacillus paracasei isolate 
      was obtained from an Egyptian cheese sample, identified and used for preparing 
      the postbiotic. The postbiotic was characterized and administered to high-fat 
      diet (HFD) albino rats (100 and 200 mg kg(-1)) for nine weeks, as compared to 
      atorvastatin (ATOR; 10 mg kg(-1)). The postbiotic could correct the disruption in 
      lipid metabolism and antioxidant enzymes in HFD rats more effectively than ATOR. 
      The two levels of the postbiotic (100 and 200 mg kg(-1)) reduced total serum 
      lipids by 29% and 34% and serum triglyceride by 32-45% of the positive control 
      level, compared to only 25% and 35% in ATOR's case, respectively. Both ATOR and 
      the postbiotic (200 mg kg(-1)) equally decreased total serum cholesterol by about 
      40% and 39%, while equally raising HDL levels by 28% and 30% of the positive 
      control. The postbiotic counteracted HFD-induced body weight increases more 
      effectively than ATOR without affecting liver and kidney functions or liver 
      histopathology, at the optimal dose of each. The postbiotic is a safer substitute 
      for ATOR in treating metabolic syndrome.
FAU - Osman, Ali
AU  - Osman A
AUID- ORCID: 0000-0001-7174-0207
AD  - Biochemistry Department, Faculty of Agriculture, Zagazig University, Zagazig 
      44511, Egypt.
FAU - El-Gazzar, Nashwa
AU  - El-Gazzar N
AUID- ORCID: 0000-0001-8229-9461
AD  - Botany and Microbiology Department, Faculty of Science, Zagazig University, 
      Zagazig 44519, Egypt.
FAU - Almanaa, Taghreed N
AU  - Almanaa TN
AD  - Department of Botany and Microbiology, College of Science, King Saud University, 
      Riyadh 11451, Saudi Arabia.
FAU - El-Hadary, Abdalla
AU  - El-Hadary A
AUID- ORCID: 0000-0002-5784-8606
AD  - Biochemistry Department, Faculty of Agriculture, Benha University, Benha 13736, 
      Egypt.
FAU - Sitohy, Mahmoud
AU  - Sitohy M
AD  - Biochemistry Department, Faculty of Agriculture, Zagazig University, Zagazig 
      44511, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20210118
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antioxidants)
RN  - 0 (Biological Products)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Biological Products/*administration & dosage
MH  - Catalase/metabolism
MH  - Glutathione Peroxidase/metabolism
MH  - Lacticaseibacillus paracasei/*metabolism
MH  - *Lipolysis
MH  - Male
MH  - Metabolic Syndrome/*drug therapy
MH  - Oxidative Stress/drug effects
MH  - Probiotics/*administration & dosage
MH  - Rats
MH  - Rats, Wistar
MH  - Superoxide Dismutase/metabolism
PMC - PMC7831067
OTO - NOTNLM
OT  - Lactobacillus paracasei
OT  - antioxidant enzymes
OT  - antioxidants activity
OT  - cell-free extract
OT  - dyslipidemia
OT  - hypercholesterolemia
OT  - metabolic syndrome
OT  - obesity
COIS- The authors declare no conflict of interest.
EDAT- 2021/01/23 06:00
MHDA- 2021/09/04 06:00
PMCR- 2021/01/18
CRDT- 2021/01/22 01:02
PHST- 2020/12/04 00:00 [received]
PHST- 2021/01/07 00:00 [revised]
PHST- 2021/01/13 00:00 [accepted]
PHST- 2021/01/22 01:02 [entrez]
PHST- 2021/01/23 06:00 [pubmed]
PHST- 2021/09/04 06:00 [medline]
PHST- 2021/01/18 00:00 [pmc-release]
AID - molecules26020472 [pii]
AID - molecules-26-00472 [pii]
AID - 10.3390/molecules26020472 [doi]
PST - epublish
SO  - Molecules. 2021 Jan 18;26(2):472. doi: 10.3390/molecules26020472.